Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX
Trv Gp Iv LLC has significantly invested in Tango Therapeutics, Inc. (NASDAQ:TNGX) by acquiring over 6.37 million shares, making it their second-largest holding. This investment, valued at approximately $120 billion, represents about 4.41% of Tango Therapeutics. Despite the company missing its recent quarterly EPS estimates, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $43.46.
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX
Trv Gp Vi LLC has acquired a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX), purchasing 194,174 shares valued at approximately $6.07 billion, making it their 4th largest position. The article highlights other institutional investments, insider selling, and current analyst ratings, which show a consensus "Moderate Buy" with an average price target of $43.46 despite a recent earnings miss. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer.
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66
H.C. Wainwright has increased its target price for Tango Therapeutics, Inc. (TNGX.O) from $66 to $68. This update reflects a positive adjustment in the firm's outlook for the biotechnology company. The news was reported by Reuters.
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift
Tango Therapeutics recently announced a wider net loss, a $400 million at-the-market equity offering, and leadership changes aimed at bolstering its commercialization efforts. These strategic moves suggest the company is preparing vopimetostat for late-stage development and commercial launch, though they also highlight potential shareholder dilution. The stock's current valuation already reflects high expectations despite the company's distant profitability.
Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright
HC Wainwright has increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $68.00 from $66.00, maintaining a "buy" rating and suggesting a significant upside. This comes despite the company reporting a quarterly loss of $0.37 per share, missing the consensus estimate. Tango Therapeutics currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $43.46.
H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com
H.C. Wainwright has increased its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) shares to $68 from $66, maintaining a Buy rating. This adjustment follows the company's Q2 2026 results, which showed a higher net loss than previously estimated, but also revealed a strong cash position of approximately $1 billion. The firm believes this cash reserve could provide an operational runway potentially into profitability, and the new target aligns with a strong Buy consensus despite a significant stock surge over the past year.
H.C. Wainwright raises Tango Therapeutics price target to $68
H.C. Wainwright increased its price target for Tango Therapeutics (NASDAQ: TNGX) to $68 from $66, while maintaining a Buy rating, following the company's Q2 2026 results. Despite Tango reporting a larger net loss than anticipated, the firm highlighted the company's strong cash position of approximately $1 billion, which could provide an operational runway into profitability. This positive outlook is echoed by other analysts, with recent upgrades and target increases from Jefferies, JPMorgan, Mizuho, and Guggenheim, reflecting ongoing advancements in their clinical trials and strategic appointments.
Stifel reiterates Tango Therapeutics stock rating with $40 target
Stifel has reaffirmed its Buy rating for Tango Therapeutics Inc. (NASDAQ:TNGX) with a price target of $40.00, despite the stock appearing overvalued relative to its Fair Value estimate. The firm anticipates positive longer follow-up data from an upcoming ESMO 2026 presentation regarding the company's vopimetostat plus RAS(ON) inhibitor combination, particularly in pancreatic ductal adenocarcinoma, which could maintain the high objective response rate. This comes amid significant clinical progress and analyst upgrades from Guggenheim, Mizuho, JPMorgan, and Jefferies, reflecting growing optimism in Tango Therapeutics' cancer treatments.
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A
An amended Schedule 13G filing for Tango Therapeutics (TNGX) reveals that Nextech Crossover I SCSp, Nextech Crossover I GP S.a r.l., and individuals Ian Charoub, Costas Constantinides, and Rocco Sgobbo now report 0 beneficial shares, equating to 0.0% ownership as of June 30, 2026. These reporting persons indicate they hold 5 percent or less of Tango Therapeutics' common stock and possess no sole or shared voting or dispositive power. The filing confirms their status below the 5% Schedule 13G reporting threshold.
Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a 6.0% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G filing. This holding amounts to 9,742,402.80 shares and signifies shared voting and dispositive power over a significant portion of Tango's common stock. The filing identifies Goldman Sachs & Co. LLC as a broker-dealer and investment adviser, with The Goldman Sachs Group, Inc. acting as a parent holding company.
Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants
Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 16,270,187 shares of Tango Therapeutics (TNGX), representing 9.8% of the company's outstanding common stock. This includes 12,277,000 directly held shares and 3,993,187 pre-funded common stock purchase warrants, which are exercisable within 60 days, subject to a 9.99% beneficial ownership limitation. The disclosure was made in an amended Schedule 13G/A SEC filing.
Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX
Handelsbanken Fonder AB has acquired 287,900 shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) for approximately $9 million, establishing a 0.20% stake in the company. Institutional investors now collectively own nearly 79% of Tango Therapeutics, a clinical-stage biotechnology company focused on precision cancer medicines. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $43.31, despite reporting a wider-than-expected quarterly loss.
Tango Therapeutics (TNGX) Is Getting Fresh Attention, What Are Investors Looking At?
Tango Therapeutics (TNGX) recently saw investor attention due to a wider Q2 net loss, the cessation of collaboration revenue, and a new US$400 million at-the-market equity offering which could dilute shareholders. Despite short-term share price drops, the stock shows strong momentum over longer periods, with significant year-to-date and one-year returns, indicating shifting expectations for its pipeline. The company trades below analyst targets and intrinsic value, presenting a potential opportunity, though it faces risks like ongoing losses and reliance on its oncology pipeline.
Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX
Tema ETFs LLC has acquired a new stake of 55,384 shares in Tango Therapeutics, Inc. (NASDAQ:TNGX), valued at approximately $1.73 million. Other institutional investors have also adjusted their holdings, and company insider Adam Crystal sold 27,000 shares. Despite missing EPS estimates, analysts maintain a "Moderate Buy" rating with an average price target of $43.31, significantly above its current trading price of $25.58.
Adage Capital discloses 3.44% Tango Therapeutics (TNGX) stake in 13G/A filing
Adage Capital Management, L.P. and associated parties have disclosed a 3.44% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G/A filing. This ownership amounts to 5,600,000 shares, with both shared voting and shared dispositive power. The percentage is calculated based on 162,814,649 outstanding shares of Tango Therapeutics.
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics (TNGX) reported a wider-than-expected loss of 37 cents per share in Q2 2026, missing the Zacks Consensus Estimate of 31 cents, leading to a 4.8% stock dip. The company recorded no collaboration revenues as its agreement with Gilead concluded, and operating expenses significantly increased due to higher R&D for clinical programs and a near doubling of general and administrative costs. Despite the earnings miss, TNGX highlighted progress in its pipeline, particularly with lead candidate vopimetostat in combination with daraxonrasib for pancreatic cancer.
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics (TNGX) reported a wider-than-expected loss of 37 cents per share in Q2 2026, missing the Zacks Consensus Estimate of 31 cents, primarily due to higher operating expenses and no collaboration revenues. Despite the earnings miss causing a 4.8% stock dip, TNGX shares have surged 197.3% year-to-date. The company is advancing its lead pipeline candidate, vopimetostat, with promising clinical data in pancreatic cancer and plans for a phase III study.
Guggenheim raises Tango Therapeutics stock price target to $35
Guggenheim raised its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) to $35 from $32, maintaining a Buy rating, following the company's Q2 2026 results and plans for a Phase 3 trial. Despite the stock's significant increase over the past year, InvestingPro suggests it is currently overvalued. The company anticipates several key updates and trial initiations in the second half of 2026.
Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes
Tango Therapeutics (TNGX) reported a net loss of US$100.9m and zero revenue for H1 2026, widening its loss from the previous year, although its balance sheet has improved due to a large equity raise earlier in 2026. The company, an early-stage oncology player, is facing scrutiny over its cash burn and reliance on its pipeline for future success, as its stock dropped about 5% today and 15% over the past 30 days. Despite recent leadership hires focused on commercialization, the absence of product revenue and increased losses highlight the significant financial pressures and the importance of successful development for the biotech firm.
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics announced its second quarter 2026 financial results, highlighting significant progress in its clinical pipeline, particularly with vopimetostat for pancreatic cancer, which showed a 92% objective response rate in Phase 1/2 trials. The company is preparing for late-stage clinical advancement and potential commercialization, supported by a strong cash position of $1.0 billion. Key leadership appointments have also been made to bolster these efforts.
Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes
Tango Therapeutics (TNGX) saw its stock drop by about 5% after reporting a widened net loss of US$100.9m and zero revenue for the first half of 2026, compared to US$8.6m in the prior year. Despite a significant equity raise earlier in the year, the company, an early-stage oncology developer, faces pressure from its cash burn and the absence of product revenue, highlighting its reliance on future funding and successful pipeline development. The balance sheet, however, is better positioned to sustain current spending, while new leadership hires suggest a focus on commercialization.
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $44.58, Implies 61% Upside
Analysts have increased the average 12-month price target for Tango Therapeutics, Inc. (TNGX) stock from $44.33 to $44.58, with a range of $24 to $69 per share. This updated target suggests a 61% potential upside based on the Aug. 10 closing price. The consensus rating from 13 analysts remains a "Buy," with 12 Buy ratings and 1 Hold.
Why is Tango Therapeutics stock sliding today?
Tango Therapeutics (TNGX) stock fell nearly 4.0% after the company reported Q2 2026 financial results that missed Wall Street expectations, with a wider net loss per share and zero revenue. Operating costs, particularly general and administrative expenses, nearly doubled year-over-year. Despite progress in clinical trials, investors focused on the financial shortfall and a mildly risk-off broader market contributed to the stock's decline.
Tango Therapeutics faces earnings test as PRMT5 data fuels rally
Tango Therapeutics (NASDAQ: TNGX) is set to report its second-quarter earnings, with investors keenly anticipating updates on its PRMT5 inhibitor programs, particularly the progress toward a Phase 3 pancreatic cancer trial. The clinical-stage biotech has seen its stock rally due to promising combination data, and analysts are bullish with a mean price target implying significant upside. Key areas of focus for investors include regulatory feedback, enrollment strategies for trials, cash burn, and data readouts for lung cancer and glioblastoma programs, especially given increasing competition in the MTAP-deleted cancer space.
Tango Therapeutics faces earnings test as PRMT5 data fuels rally
Tango Therapeutics (TNGX) is set to report its second-quarter results, with investors closely watching for updates on its PRMT5 inhibitor programs and its path to a pivotal pancreatic cancer trial. The company's stock has rallied significantly due to promising combination data, and analysts are largely bullish, expecting clarity on regulatory feedback, enrollment strategies, and cash burn. The focus will be on whether Tango can translate its clinical success into a clear regulatory and commercial pathway amidst intensifying competitive dynamics.
Tango Therapeutics, Inc. Q2 2026: Revenue $0 Net loss $55.34M, EPS ($0.37) — 10-Q Summary
Tango Therapeutics, Inc. reported Q2 2026 financial results with $0 revenue, a net loss of $55.34 million, and a diluted EPS loss of $0.37. The company's financial performance worsened year-over-year due to increased spending on its PRMT5 programs and expanded clinical operations. Despite the losses, Tango Therapeutics is advancing Phase 1/2 vopimetostat combination trials and is planning a Phase 3 study for MTAP-deleted PDAC.
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics announced its second-quarter 2026 financial results, highlighting a pivotal period with positive Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer, achieving a 92% objective response rate. The company is preparing for late-stage clinical advancement and has strengthened its leadership team with new appointments to support commercialization efforts. Tango reported a cash position of $1.0 billion as of June 30, 2026, which is expected to fund its operating plan through planned development and commercialization preparation.
345,156 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. recently acquired 345,156 shares of Tango Therapeutics (NASDAQ:TNGX) worth approximately $10.79 million, giving them a 0.24% stake in the company. Other institutional investors also adjusted their positions in Tango Therapeutics, while insider Adam Crystal sold 27,000 shares for about $798,930. The company reported a quarterly EPS in line with analyst expectations and maintains a "Moderate Buy" consensus rating with an average price target of $42.15.
Form 8K Tango Therapeutics Inc For: 7 August By Investing.com
This article announces that Tango Therapeutics Inc. filed a Form 8K on August 7th. It is a brief financial news update from Investing.com, highlighting the filing with the Securities and Exchange Commission (SEC). The article also notes a 6.66% decline in Tango Therapeutics' stock symbol TNGX.
Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure
Tango Therapeutics announced that Executive Chair Dr. Barbara Weber's employment ended on August 3, 2026, and she resigned from all positions without disagreement. Her departure aligns with an amended employment agreement, and she will receive a separation package including salary continuation, COBRA reimbursement, and accelerated equity vesting. This transition is presented as an orderly contractual change, aiming to assure investors of governance stability amidst her departure.
Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.1% - What's Next?
Tango Therapeutics (NASDAQ:TNGX) experienced a 6.1% decline in its share price during midday trading, closing at $27.24 with a significant 86% decrease in trading volume compared to its average. Despite the drop, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $42.15. The company recently met earnings per share expectations, and institutional investors hold a substantial portion of its shares, although an insider recently sold a considerable block of stock.
Tango Therapeutics (NASDAQ: TNGX) outlines Barbara Weber separation package
Tango Therapeutics (NASDAQ: TNGX) has detailed the separation agreement with its former Executive Chair, Dr. Barbara Weber, whose employment and board roles ended on August 3, 2026. The agreement, executed on August 6, 2026, includes base-salary severance and COBRA reimbursement through December 31, 2026, full acceleration of outstanding options and RSUs, and a pro-rata 2026 annual incentive. These benefits are conditional upon her not revoking the agreement.
Tango Therapeutics Announces Executive Chair Transition
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that Dr. Barbara Weber, Executive Chairman of its Board of Directors, will be stepping down to pursue other interests. The company expressed gratitude for her vision, leadership, and commitment. Tango Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision cancer medicines using the principle of synthetic lethality.
Form 8K Tango Therapeutics Inc For: 7 August By Investing.com
This article announces that Tango Therapeutics Inc. filed a Form 8K on August 7. The filing is brief, simply stating the company name and the filing date, and does not provide further details within the article content.
Certain Stock Options of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026.
Certain stock options of Tango Therapeutics, Inc. (TNGX) are under a 60-day lock-up agreement, preventing sales or transfers from June 9, 2026, until August 8, 2026. This restriction applies to directors and executive officers and covers common stock and convertible securities. The agreement aims to stabilize the stock price after an offering, with J.P. Morgan Securities LLC and Leerink Partners LLC managing exceptions.
Tango Therapeutics Announces Executive Chair Transition
Tango Therapeutics announced that Dr. Barbara Weber, Executive Chairman of its Board of Directors, is stepping down due to other pursuits. The company expressed gratitude for her contributions to its vision, leadership, and commitment to precision cancer medicine. Tango Therapeutics is a clinical-stage biotechnology company focused on developing therapies using synthetic lethality for cancer treatment.
Form 8K Tango Therapeutics Inc For: 6 August By Investing.com
This article reports that Tango Therapeutics Inc. filed a Form 8K on August 6th. The filing is an important regulatory disclosure for publicly traded companies. The content of the 8K filing itself is not detailed in the provided text.
Tango Therapeutics Announces Executive Chair Transition
Tango Therapeutics announced that Dr. Barbara Weber, Executive Chairman of its Board of Directors, is stepping down to pursue other interests. The company expressed profound gratitude for her vision and leadership, acknowledging her contributions to its groundbreaking work in precision cancer medicines. Dr. Malte Peters, Tango's President, affirmed the company's strong position to continue its achievements.
Tango Therapeutics executive chair Barbara Weber steps down, exits board
Barbara Weber has stepped down as Executive Chair of Tango Therapeutics and exited her board seat, effective August 3, 2026. The company stated that her departure was not due to any disagreements regarding company operations, practices, or policies. This news was generated by AI using an SEC filing from Tango Therapeutics.
Tango Therapeutics stock surges 45% on pancreatic cancer data
Tango Therapeutics' stock surged 45% after announcing positive initial data from its Phase 1/2 trial for a pancreatic cancer treatment. A combination of vopimetostat and daraxonrasib showed a 92% objective response rate and 90% 6-month progression-free survival in patients with MTAP-deleted and RAS-mutant pancreatic cancer. The company plans to advance the vopimetostat plus daraxonrasib combination into Phase 3 development for first-line treatment.
Tango Therapeutics, Inc. (TNGX) president exercises options and sells shares
Crystal Adam, President, R&D at Tango Therapeutics, Inc. (TNGX), exercised stock options for 27,000 shares at $5.20 each and simultaneously sold all 27,000 shares in two tranches at weighted average prices of $26.7895 and $27.3509 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on October 27, 2025. Following these transactions, Adam holds 287,040 stock options to purchase common shares and 115,743 common shares.
TNG Therapeutics (TNGX) insider schedules 81,000-share option-related stock sale
Adam Crystal, an insider at TNG Therapeutics Inc. (TNGX), has filed a notice to sell 81,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 3, 2026, following the exercise of stock options, with an aggregate value of $2,201,580.00. This filing also discloses previous Rule 10b5-1 sales totaling 54,000 shares in June and July 2026. The stock will be sold on NASDAQ.
Tango Therapeutics Inc (TNGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides an overview of Tango Therapeutics Inc (TNGX), including its current stock price and market capitalization. It attempts to present a revenue breakdown by business segment and region, but notes that this relevant data has not yet been disclosed by the company. The article focuses on the lack of publicly available detailed financial segment information for TNGX.
Tango Therapeutics Inc (TNGX) Financial Health: Profitability & Balance Sheet Analysis
Tango Therapeutics Inc (TNGX) has a robust financial status with a score of 8.24, ranking 57th in the Biotechnology & Medical Research industry, despite a 100% year-over-year decrease in quarterly revenue and a 14.14% decrease in net profit. The analysis highlights high operating efficiency and strong growth potential, although several key financial data points have not yet been disclosed by the company.
Tango Therapeutics, Inc. Revenue Breakdown – NASDAQ:TNGX
Tango Therapeutics, Inc. (NASDAQ: TNGX) generated $62.38 million USD in revenue last year, primarily from its Oncology Therapies segment. This marks an increase from the previous year's $42.07 million USD. The majority of this revenue, $62.38 million USD, originated from the United States.
Tango Therapeutics Inc (TNGX) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Tango Therapeutics Inc (TNGX), covering operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and TNGX's recent performance in these areas, such as its operating cash flow of -138.89M in fiscal 2025 and capital expenditures of 1.05M in the most recent quarter.
Tango Therapeutics Inc (TNGX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Tango Therapeutics Inc (TNGX), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activities by top firms. The report also lists related ETFs that include TNGX in their portfolios.
TradingKey
This article provides a detailed quarterly and annual income statement for Tango Therapeutics Inc (TNGX). It includes key financial metrics such as total revenue, operating expenses, research and development expenses, operating profit, net non-operating interest income/expenses, other non-operating income/expenses, income before and after tax, net income, and earnings per share. The article also features an FAQ section explaining how to read an income statement, the difference between quarterly and annual statements, the meaning of YOY, and which metrics are most important for analyzing TNGX stock.
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
Wall Street analysts project a significant upside for Tango Therapeutics (TNGX), with a mean price target suggesting a 49.5% increase. Despite some variability in individual estimates, there's strong agreement among analysts regarding the company's potential for better-than-expected earnings, reinforced by a positive trend in EPS estimate revisions and a Zacks Rank #2 (Buy). Investors are advised to treat price targets with skepticism but consider the implications of strong analyst agreement and improving earnings prospects.
Tango Therapeutics, Inc. (TNGX) stock price, news, quote and history
This article provides comprehensive financial information for Tango Therapeutics, Inc. (TNGX), including its current stock price, historical data, recent news, and analyst ratings. It details the company's focus on precision oncology and its drug development pipeline. The report also includes performance metrics, earnings trends, and a comparison with similar biotechnology companies.
